All News

In a 64-35 vote, the Senate approved the seventeenth fix to the sustainable growth rate (SGR) payment formula.

The ASCO task force has identified 3 goals for its strategic value initiative. First is that oncologists will have the skills and tools needed to evaluate the relative value of interventions, and will use these when discussing treatment options with their patients. Second is to have information readily accessible to help patients select high-value treatment that meets their individual needs. Third is to have an algorithm that can be used by those responsible for covering the costs of cancer care to define and assess the value of treatment options.

By passing this law, EU lawmakers loosen the grip of pharmaceutical companies on how and when physicians prescribe a particular drug.

DNA repair is a prime mechanism for preventing DNA damage, mutation, and cancers. Adopting a functional approach, we examined the association with lung cancer risk of an integrated DNA repair score, measured by a panel of three enzymatic DNA repair activities in peripheral blood mononuclear cells.

As retail clinics plan to have a role in improving health outcomes, they must achieve the 3 components of the triple aim: access, quality, and cost.

The American Society of Clinical Oncology (ASCO) has launched a strategic initiative to define value in cancer care.

Two Republicans dueled over Medicaid this morning, as the Senate's foremost opponent of expansion accused another senator of taking the "easy" route in rolling out a plan that would increase coverage.

Before the next season starts, states will be working with insurance companies to craft new plans and oversee new premium rates based on this year's claims. Most states also plan to tinker with or overhaul their websites.

Researchers discovered that microscopic "bubbles" are safe and effective storage lockers for harmful isotopes that emit ionizing radiation for treating tumors. The findings can benefit patient health and advance radiation therapy used to treat cancer and other diseases.

In February, Pfizer announced encouraging results for palbociclib with statistically significant and clinically meaningful improvement in progression-free survival (PFS) for women with a certain type of advance breast cancer in a mid-stage, or phase III, study.

GlaxoSmithKline has been forced to halt a Phase III trial assessing its MAGE-A3 cancer immunotherapeutic in patients with non-small cell lung cancer (NSCLC).

A DNA methylation marker test performed on urine samples obtained from patients with non-muscle-invasive bladder cancer (NMIBC) has the ability to predict tumor recurrence with both high sensitivity and specificity.

The Safety Assurance Factors for Electronic Health Record (EHR) Resilience, or SAFER guidelines, could assist healthcare providers as they integrate technology into their everyday practices.

Recent research has raised the possibility that low-dose aspirin could add extra years to the lives of colon cancer patients. Now, a new study suggests that only certain patients may gain a survival benefit by taking aspirin after diagnosis.

Nonprofit, member-owned cooperatives aim to create more competition and drive prices down.

Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. patent for the drugmaker' s blockbuster lung-cancer drug, Alimta.

Saladax Biomedical's MY5-FU blood test will help personalize and optimize 5-fluorouracil dosing in cancer patients.

Big data, electronic health records, online health insurance portals-countless technology innovations are emerging, but how important are they for health leaders to adopt? According to analysts at Forrester Research, a global research and advisory firm, it's not only extremely imperative, but a matter of organizational survival.

Patients with resected non-small cell lung cancer (NSCLC) are at risk for recurrence of disease, but currently there are no tools to predict which patients are at highest risk. The authors set out to create a risk model incorporating both clinical data and biomarkers.

The Senate approved a bill Monday evening that prevents steep cuts to Medicare physician payments from going into effect for one year and delays the conversion to ICD-10 diagnostic and procedure codes for at least one year.

The public will learn for the first time this fall exactly how much their doctors are paid by the drug companies and devicemakers whose products they use. But don't expect it to be the end of the inquiry.

Rates of new cancer cases in the United States have fallen slightly in recent years, according to a new report from the Centers for Disease Control and Prevention.

The Medicare Payment Advisory Commission (MedPAC) recently aired concerns as to whether the patient-centered medical home (PCMH) can serve as a model for providing value-based care. In particular, several members asserted that the medical home model may have a real cost disadvantage for health systems. They explained that without evidence-based research, it is difficult to determine if the model encourages practices to use their cost savings to improve care.

A new oral angiogenesis inhibitor for the treatment of lung cancer could be edging closer to the market: Approval application for nintedanib (Boehringer Ingelheim) has been filed in Europe and is being prepared for the United States.

Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.

As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.

Healthcare spending rose at the fastest pace in 10 years last quarter, a development that could foreshadow higher costs for consumers this year.

Doctors are trying to stoke a rebellion against the doc fix.

As the quality and cost transparency movements gain support within the healthcare industry, a more important question persists: what will actually work for consumers?

The National Comprehensive Cancer Network® (NCCN) will host Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies on April 25, 2014 in Bethesda, Maryland, as part of the NCCN Oncology Policy Program.